ACADIA Pharmaceuticals (ACAD) News Today $22.95 +0.15 (+0.66%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$22.94 -0.01 (-0.04%) As of 04:29 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACAD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Yousif Capital Management LLC Makes New $764,000 Investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Yousif Capital Management LLC bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 45,983 shares ofJune 20 at 3:26 AM | marketbeat.comHigh Growth Tech Stocks In The US Market June 2025June 19 at 2:19 AM | finance.yahoo.comACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have earned a 21% CAGR over the last three yearsJune 19 at 2:19 AM | finance.yahoo.comAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 17 at 4:05 PM | businesswire.comGAMMA Investing LLC Increases Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)GAMMA Investing LLC raised its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 11,981.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 58,351 shares of the biopharmaceuticalJune 17 at 3:03 AM | marketbeat.comCantor Fitzgerald Sticks to Their Buy Rating for ACADIA Pharmaceuticals (ACAD)June 16, 2025 | theglobeandmail.com13 Biotech Stocks with Huge Upside PotentialJune 13, 2025 | insidermonkey.comRhumbline Advisers Increases Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Rhumbline Advisers boosted its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 100.9% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 352,716 shares of the biopharmaceutical company'sJune 13, 2025 | marketbeat.comAssenagon Asset Management S.A. Invests $60.85 Million in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Assenagon Asset Management S.A. bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 3,663,145 shares of the biopharmJune 12, 2025 | marketbeat.comCantor Fitzgerald Forecasts ACAD FY2026 EarningsJune 12, 2025 | americanbankingnews.comUS Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s MedicationJune 11, 2025 | insidermonkey.comAcadia Pharmaceuticals Gets Another Court Win for Parkinson's TreatmentJune 11, 2025 | marketwatch.comUS appeals court confirms patent validity of Acadia's Parkinson's drugJune 11, 2025 | msn.comAnalysts Issue Forecasts for ACAD FY2026 EarningsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst J. Kim expects that the biopharmaceutical company will earn $0.8June 10, 2025 | marketbeat.comU.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter PatentJune 9, 2025 | businesswire.comBrokers Offer Predictions for ACAD FY2025 EarningsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Cantor Fitzgerald issued their FY2025 EPS estimates for shares of ACADIA Pharmaceuticals in a research note issued on Thursday, June 5th. Cantor Fitzgerald analyst J. Kim expects that the biopharmaceutical company will earn $0.51 per shareJune 9, 2025 | marketbeat.comInsider Selling: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Director Sells 14,446 Shares of StockJune 7, 2025 | insidertrades.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for ACADIA Pharmaceuticals (NASDAQ:ACAD) StockJPMorgan Chase & Co. boosted their target price on shares of ACADIA Pharmaceuticals from $26.00 to $30.00 and gave the stock an "overweight" rating in a report on Friday.June 6, 2025 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded to Strong-Buy at Cantor FitzgeraldCantor Fitzgerald raised shares of ACADIA Pharmaceuticals to a "strong-buy" rating in a research note on Thursday.June 6, 2025 | marketbeat.comBofA Securities Lifts ACADIA Pharmaceuticals Inc. (ACAD)’s Price Target To $23, Maintains Neutral RatingJune 6, 2025 | msn.comThe Analyst Verdict: ACADIA Pharmaceuticals In The Eyes Of 11 ExpertsJune 6, 2025 | benzinga.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Director Laura Brege Sells 14,446 SharesACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) Director Laura Brege sold 14,446 shares of the business's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $21.78, for a total value of $314,633.88. Following the completion of the sale, the director now directly owns 15,095 shares of the company's stock, valued at $328,769.10. The trade was a 48.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.June 6, 2025 | marketbeat.comBank of America Forecasts Strong Price Appreciation for ACADIA Pharmaceuticals (NASDAQ:ACAD) StockBank of America raised their price target on ACADIA Pharmaceuticals to $23.00 and gave the stock a "hold" rating in a research report on Thursday.June 5, 2025 | marketbeat.comAcadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025June 5, 2025 | businesswire.comHennion & Walsh Asset Management Inc. Has $2.18 Million Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Hennion & Walsh Asset Management Inc. raised its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 26.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 131,061 shares of the biopharmaceuticalJune 5, 2025 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 15.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 219,125 sJune 5, 2025 | marketbeat.comSummit Global Investments Buys Shares of 23,934 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Summit Global Investments bought a new stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 23,934 shares of the biopharmaceutical company's stock, valued at approximately $398,000. OtherJune 2, 2025 | marketbeat.comMackenzie Financial Corp Purchases 32,833 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Mackenzie Financial Corp increased its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 180.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 51,065 shares of the biopharmaceutical company'sJune 2, 2025 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Average Rating of "Moderate Buy" by BrokeragesShares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the fourteen brokerages that are presently covering the stock, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation and nine haveJune 1, 2025 | marketbeat.comZacks Research Has Negative Outlook of ACAD FY2025 EarningsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Analysts at Zacks Research cut their FY2025 EPS estimates for ACADIA Pharmaceuticals in a note issued to investors on Wednesday, May 28th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will earn $May 31, 2025 | marketbeat.comZacks Research Has Pessimistic Outlook of ACAD Q2 EarningsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Investment analysts at Zacks Research cut their Q2 2025 EPS estimates for ACADIA Pharmaceuticals in a research report issued on Wednesday, May 28th. Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company wilMay 30, 2025 | marketbeat.comAcadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceMay 29, 2025 | businesswire.comPhocas Financial Corp. Increases Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Phocas Financial Corp. lifted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 79.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 107,811 shares of the biopharmaceutical company's stock after buying an aMay 29, 2025 | marketbeat.comJefferies Financial Group Inc. Invests $2.11 Million in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Jefferies Financial Group Inc. purchased a new stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 114,766 shares of the biophMay 29, 2025 | marketbeat.comWoodline Partners LP Buys Shares of 26,765 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Woodline Partners LP bought a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 26,765 shares of the biopharmaceutical company's stMay 28, 2025 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Squarepoint Ops LLCSquarepoint Ops LLC reduced its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 67.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 185,313 shares of the biopharmaMay 28, 2025 | marketbeat.comAcadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease FranchiseMay 27, 2025 | businesswire.comRett Syndrome Market Sees Momentum with Novel Gene and Protein-Targeted Therapies | DelveInsightMay 26, 2025 | finance.yahoo.com55,133 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Bought by CTC Alternative Strategies Ltd.CTC Alternative Strategies Ltd. acquired a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 55,133 shares of the biopharmaceutical companMay 26, 2025 | marketbeat.comNeo Ivy Capital Management Raises Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Neo Ivy Capital Management boosted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 1,551.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5May 26, 2025 | marketbeat.comVoloridge Investment Management LLC Decreases Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Voloridge Investment Management LLC lessened its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 44.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 725,508 shares of the biopharmaceutical cMay 26, 2025 | marketbeat.com55,566 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Purchased by Alpine Global Management LLCAlpine Global Management LLC acquired a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 55,566 shares of the biopharmaceutical company's stock, valued at approMay 25, 2025 | marketbeat.comJT Stratford LLC Invests $278,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)JT Stratford LLC purchased a new stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 15,170 shares of the biopharmaceutical company's stock, valueMay 25, 2025 | marketbeat.comNuveen Asset Management LLC Reduces Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Nuveen Asset Management LLC trimmed its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 1.2% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,347,093 shares of the biopharmaceutical company's stock after sMay 25, 2025 | marketbeat.comBank of America Corp DE Raises Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Bank of America Corp DE boosted its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 41.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 680,853 shares of the biopharmaceutiMay 25, 2025 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Stock Holdings Lifted by Two Sigma Investments LPTwo Sigma Investments LP grew its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 12.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,243,442 shares of the biopharmaceutical compaMay 24, 2025 | marketbeat.comDeutsche Bank Upgrades ACADIA Pharmaceuticals (BMV:ACAD)May 23, 2025 | nasdaq.comACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Up 3.5% After Analyst UpgradeACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Up 3.5% Following Analyst UpgradeMay 23, 2025 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $35.00 at Deutsche Bank AktiengesellschaftDeutsche Bank Aktiengesellschaft boosted their price target on ACADIA Pharmaceuticals to $35.00 and gave the company a "buy" rating in a report on Wednesday.May 23, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for ACAD FY2027 Earnings?ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - HC Wainwright lifted their FY2027 earnings per share estimates for ACADIA Pharmaceuticals in a note issued to investors on Monday, May 19th. HC Wainwright analyst A. Fein now anticipates that the biopharmaceutical company will post earningMay 23, 2025 | marketbeat.com Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Media Mentions By Week ACAD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACAD News Sentiment▼0.740.69▲Average Medical News Sentiment ACAD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACAD Articles This Week▼79▲ACAD Articles Average Week Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Summit Therapeutics News Genmab A/S News Intra-Cellular Therapies News Dr. Reddy's Laboratories News Ascendis Pharma A/S News Viatris News Qiagen News Moderna News Blueprint Medicines News BridgeBio Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACAD) was last updated on 6/20/2025 by MarketBeat.com Staff From Our PartnersWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… and it's all thanks to President Trump. His administr...InvestorPlace | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredWar-Proof Power Why This "Weird" Government Land Auction Was No Ordinary Sale When 218,000 acres of land... smack in the m...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACAD Stock Free ACAD Stock Alerts